Chan Whiting

Chan Whiting has over 20 years of work experience in the biotech industry. They are currently serving as the Chief Development Officer (CDO) and Head of R&D at Actym Therapeutics, Inc. since September 2021. Prior to this, they held the position of Senior Vice President and Head of R&D at Tempest Therapeutics from October 2017 to September 2021.

From 2014 to 2017, Whiting worked at Aduro Biotech, where they held various roles including Director and Head of Immune Monitoring and Biomarker Development, Project Team Lead for the NeoAntigen Vaccine Program, and Associate Director and Head of Immune Monitoring and Biomarker Development.

Before joining Aduro Biotech, Whiting served as a Senior Research Scientist at Stanford University from November 2009 to June 2014. During their time at Stanford, they conducted research on the molecular basis of autoimmunity with a focus on Type 1 diabetes, Rheumatoid arthritis, and CD/IBD, and managed scientific collaborations and projects.

Prior to Stanford, Whiting worked as a Scientific and Program Manager at Qiagen (formerly Ingenuity Systems) from November 2007 to December 2009, where they oversaw a multi-center collaboration for therapeutic target discovery and validation, and managed scientific software product development.

Earlier in their career, Whiting worked as a Scientist and Project Team Lead at Entelos from August 2004 to November 2007, as well as a Post Doctoral Scholar at Stanford University from May 2002 to August 2004. They also served as a Post Doctoral Fellow at Amgen (formerly Tularik, Inc) from June 2001 to May 2002.

Overall, Whiting has extensive experience in R&D, immune monitoring, biomarker development, and scientific management, and has made significant contributions to the biotech industry.

Chan Whiting attended UCLA from 1990 to 1993, where they earned a Bachelor of Science (B.S.) degree in Biochemistry. They then pursued further education at UCLA from 1996 to 2001 and obtained a Ph.D. in the fields of biochemistry, immunology, and infectious disease. Finally, from 2002 to 2004, they attended Stanford University to study Autoimmunity, although no specific degree is mentioned.